










ORIGINAL ARTICLE

Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacterales infection

Matteo Rinaldi^{1,2}  | Cecilia Bonazzetti^{1,2} | Mena Gallo² | Giuseppe Ferraro^{1,2} |
 Maristela Freire³  | Débora Raquel Benedita Terrabuio⁴ | Francesco Tandoi⁵ |
 Renato Romagnoli⁵ | Francesco Giuseppe De Rosa⁶ | Alessandra Mularoni⁷  |
 Alberto Ferrarese⁸ | Patrizia Burra⁸ | Marcia Halpern⁹ | Elizabeth Balbi⁹ |
 Jacques Simkins¹⁰  | Lilian Abbo¹¹  | Ignacio Morrás¹² | Mireia Cantero¹³ |
 Laura Alagna¹⁴ | Alessandra Bandera^{14,15} | Wanessa Trindade Clemente¹⁶ |
 Maricela Valerio¹⁷  | Ainhoa Fernández¹⁸ | Patricia Muñoz¹⁷  | Liran Statlender¹⁹ |
 Dafna Yahav²⁰  | Luis Fernando Aranha Camargo²¹ | Evelyne Santana Girão²² |
 Paolo Grossi²³ | Pierluigi Viale^{1,2} | Stefania Curti² | Maddalena Giannella^{1,2}  |
 CRECOOLT study group[#]

Correspondence

Maddalena Giannella, Infectious Disease Unit,
IRCCS Policlinico S. Orsola-Malpighi, Via
Massarenti 11, 40138 Bologna, Italy.
Email: maddalena.giannella@unibo.it

Abstract

Background: Management of infections due to carbapenemase-resistant Enterobacterales (CRE) in solid organ transplant (SOT) recipients remains a difficult challenge. The INCREMENT-SOT-CPE score has been specifically developed from SOT recipients to stratify mortality risk, but an external validation is lacking.

Methods: Multicenter retrospective cohort study of liver transplant (LT) recipients colonized with CRE infection who developed infection after transplant over 7-year period. Primary endpoint was all-cause 30-day mortality from infection onset. A comparison between INCREMENT-SOT-CPE and other selected scores was performed. A two-level mixed effects logistic regression model with random effects for the center was fitted. Performance characteristics at optimal cut-point were calculated. Multivariable Cox regression analysis of risk factors for all-cause 30-day mortality was carried out.

Results: Overall, 250 CRE carriers developed infection after LT and were analyzed. The median age was 55 years (interquartile range [IQR]: 46–62) and 157 were males (62.8%). All-cause 30-day mortality was 35.6%. A sequential organ failure

Abbreviations: BSI, bloodstream infection; CMV, Cytomegalovirus; CRE, carbapenem-resistant Enterobacterales; ICS, INCREMENT-CPE score; ICU, intensive care unit; LT, liver transplant; MELD, model for end-stage liver disease; NPV, negative predictive value; PPV, positive predictive value; SOFA, sequential organ failure assessment; SOT, solid organ transplant.

[#]CRECOOLT study group details are available in appendix section.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Transplant Infectious Disease* published by Wiley Periodicals LLC.



assessment (SOFA) score ≥ 11 showed a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 69.7%, 76.4%, 62.0%, 82.0%, and 74.0%, respectively. An INCREMENT-SOT-CPE ≥ 11 reported a sensitivity, specificity, PPV, NPV, and accuracy of 73.0%, 62.1%, 51.6%, 80.6% and 66.0%, respectively. At multivariable analysis acute renal failure, prolonged mechanical ventilation, INCREMENT-SOT-CPE score ≥ 11 and SOFA score ≥ 11 were independently associated with all-cause 30-day mortality, while a tigecycline-based targeted regimen was found to be protective.

Conclusions: Both INCREMENT-SOT-CPE ≥ 11 and SOFA ≥ 11 were identified as strong predictors of all-cause 30-day mortality in a large cohort of CRE carriers developing infection after LT.

KEYWORDS

CRE infection, INCREMENT-SOT-CPE score, liver transplantation, SOT

1 | INTRODUCTION

Infections due to carbapenem-resistant Enterobacterales (CRE) are increasing worldwide and remain a major issue in endemic centers.¹ Solid organ transplant (SOT) recipients have an increased risk for CRE colonization and subsequent infection, with high risk of death, attesting between 30% and 50%.^{2,3} These high mortality rates justify the efforts to recognize specific risk factors, preemptive strategies, and risk stratification tools in order to better address available interventions.⁴ Recently, the INCREMENT-CPE score (ICS) was developed and externally validated in a large cohort of intensive care unit (ICU) patients with CRE bacteraemia, exhibiting a predictive accuracy comparable to sequential organ failure assessment (SOFA) and Pitt scores.⁵ Furthermore, such score was validated in patients with colistin-resistant pathogens⁶ and in patients treated with ceftazidime/avibactam,⁷ showing similar results. However, these studies were not focused on SOT recipients. Therefore, a new score (INCREMENT-SOT-CPE) was derived in a retrospective cohort of SOT recipients, showing an area under the curve (AUROC) of 0.82 (95% confidence interval [CI]: 0.76–0.88) on predicting 30-day mortality.⁸ However, such score was not validated in an external cohort. The aim of our study was to evaluate the accuracy of the INCREMENT-SOT-CPE score and other main scores on predicting mortality in a large international multicenter cohort of liver transplant (LT) recipients colonized with CRE who developed CRE infection after transplant.

2 | MATERIALS AND METHODS

2.1 | Study design

Multicenter multinational retrospective cohort study was performed between January 2010 and December 2017. Data were gathered from clinical charts and hospital electronic records, de-identified before

entry into a standardized electronic case report form (eCRF), and managed using REDCap electronic data capture tool, hosted by Alma Mater University of Bologna^{9,10} from July 2021 to October 2021. The accuracy of data was checked by an investigator of the coordinating center (Matteo Rinaldi). Queries for incongruous or missing data were submitted to investigators to ensure high quality and completeness. CRE-infected patients were extracted from a previous multicenter cohort of LT carriers.⁴ The study was first approved by Institutional Review Board (IRB) of the promoting center (n. 155/2019/Oss/AOUBO on March 20, 2019), then by IRB of all participating centers.

2.2 | Setting

Fourteen hospitals performing LT participated in the study: five from Italy (Bologna, Turin, Padua, Palermo, and Milan); five from Brazil (two in São Paulo, one in Fortaleza, one in Belo Horizonte, and one in Rio de Janeiro); two from Spain (Madrid and Majadahonda); one from the United States (Miami); and one from Israel (Petah-Tikva). In each center, an active surveillance screening for CRE colonization is in force.

2.3 | Study population

All consecutive adult (≥ 18 years) patients colonized with CRE prior or post LT who developed a CRE infection within 180 days after LT were analyzed. Only the first CRE infection was considered with a minimum follow-up of 30 days after infection onset. CRE was defined as any Enterobacterales displaying in vitro non-susceptibility to any of the carbapenems according to the criteria (CLSI or EUCAST) adopted at the participating center during the study period. The colonization status was defined as isolation of CRE from rectal swabs or other samples other than blood cultures or sterile fluids (e.g., urine, respiratory samples, superficial skin samples) in absence of symptoms and signs

of infection. CRE infection was defined accordingly with Centers for Disease Control and Prevention (CDC) criteria.¹¹ The assessment of CRE infection was established by the local investigator and revised by an investigator of the promoting center (Matteo Rinaldi); in case of no agreement, a third blinded investigator of the promoting center (Madalena Giannella) was asked to revise the case for establishing the final diagnosis.

2.4 | Validation of the INCREMENT-SOT-CPE score and other scores

The primary objective was to validate in our cohort, the prognostic performance of the INCREMENT-SOT-CPE score in predicting 30-day mortality. The accuracy of such score was further compared with other main prognostic scores: SOFA score, PITT score, qPITT score, and ICS.¹²⁻¹⁵

Study variables included demographic data (age and sex), comorbidities according to Charlson index, underlying liver disease, and severity of liver disease according to model for end-stage liver disease (MELD) at inclusion in waiting list and at LT. Complications occurring from LT to the diagnosis of CRE infection were recorded and included: re-intervention, acute kidney injury (AKI) according to KDIGO criteria,¹⁶ renal replacement therapy (RRT), prolonged (≥ 48 h) mechanical ventilation (MV), graft dysfunction (primary or secondary), biopsy-proven rejection, re-transplantation, and *Cytomegalovirus* (CMV) DNAemia greater than 100 000 copies/mL.¹⁷ Data regarding empirical and targeted anti-CRE treatments were collected. Finally, variables included in INCREMENT-SOT-CPE, ICS, SOFA, PITT, and qPITT scores were also collected at CRE infection onset.

2.5 | Missing data

A complete case analysis was performed.

2.6 | Statistical analysis methods

Categorical variables were reported as counts and percentages. Continuous variables were expressed as mean \pm standard deviation (SD) if normally distributed, or as median and interquartile range (IQR) if non-normally distributed.

For the comparison between survivors and non-survivors, categorical variables were compared using χ^2 test or Fisher's exact test as appropriate, whereas continuous variables were compared using Student's *t*-test or Mann-Whitney *U* test depending on whether normally distributed or not.

A comparison between INCREMENT-SOT-CPE and other selected scores (i.e., ICS, PITT, qPITT, and SOFA) was performed by calculating the area under the receiver operating characteristic (ROC) curve for observed data. Each score was assessed as a binary variable on the basis of the optimal cut-off according to Youden's criterion.¹⁸ We used

a two-level mixed effects logistic regression model, where the center identifies the group structure for the random effects at that level (i.e., data clustered within centers).¹⁹⁻²¹ A likelihood-ratio test was used to compare this model with ordinary logistic regression. Performance characteristics at cut-point (i.e., sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], and accuracy) were calculated along with their 95% CI. Given that the INCREMENT-SOT-CPE score was developed exclusively for patients with bloodstream infection (BSI), subgroup analyses among patients with and without BSI were performed (see Tables S1-S4 and Figures S1 and S2). In addition to that, considering that SOFA is especially aimed at critical patients, subgroup analyses among patients admitted or not to the ICU at time of developing the infection were carried out (see Tables S5 and S6 and Figures S3 and S4).

Multivariable Cox regression analysis for all-cause 30-day mortality was performed considering patients from the day of infection diagnosis until death or 30 days, whichever occurred first. We used a Cox model with gamma-distributed frailty, where the center defines the group over which frailties are shared.²² A likelihood-ratio test was used to verify if correlation within centers cannot be ignored. The covariates to be included in the multivariable Cox regression model were selected through a backward stepwise selection strategy (*p*-value for inclusion $\leq .1$, *p*-value for exclusion $> .2$). Variables were primarily entered according to clinical relevance and lack of collinearity. The full model included the following variables: gender, acute renal failure, prolonged mechanical ventilation, targeted polymyxin-based regimen, targeted aminoglycoside-based regimen, targeted tigecycline-based regimen, INCREMENT-SOT-CPE, and SOFA score. These scores were entered as binary variables according to optimal cut-offs based on Youden's criterion. The reduced model finally retained: acute renal failure, prolonged mechanical ventilation, targeted tigecycline-based regimen, INCREMENT-SOT-CPE, and SOFA score. The proportional hazards assumption was checked by plotting a log-log graph of survival curves along with statistical tests and graphical diagnostics based on Schoenfeld residuals (see Figures S5 and S6). If proportional hazard assumption was violated for a variable, that is, for that variable the hazard changed over time, the variable was included in the model assuming that has time-dependent coefficients through the use of a step function reporting different coefficients, and thus also different hazard ratios, over different time intervals. Time intervals selection was based on visual analysis of the log-log plot of survival curves (Figure S6).²³ A final Cox model with shared frailty that included a time-dependent covariate for SOFA was fitted.

All the analyses were carried out using Stata 16.1 (Stata Corp., College Station, TX, USA). All statistical tests were two-sided and an alpha error of .05 was accepted.

3 | RESULTS

Overall, 250 out of 840 CRE carriers developed infection after LT recipients and were analyzed. The distribution of events across participating centers is shown in Table S1. The principal characteristics of study



population are shown in Table 1. Briefly, the median age was 55 years (IQR 46–62) and the proportion of men was 62.8% ($n = 157$). The mean Charlson index was 5.5 (SD 2.0), the primary indication for LT was viral hepatitis in 114/250 subjects (45.6%), followed by alcoholic cirrhosis (49/250, 19.6%). Hepatocellular carcinoma (HCC) was diagnosed in almost one third of patients (71/250, 28.4%). MELD at inclusion in waiting list and at LT was 19 (IQR 14–27) and 25 (IQR 16–32), respectively. Among post-LT complications, acute renal failure occurred in 176/250 cases (70.4%), followed by prolonged mechanical ventilation (132/250, 52.8%) and needing of a surgical re-intervention (123/250, 49.2%). CMV infection was diagnosed in 70/250 cases (28%), 146/250 patients (58.4%) had an infection other than CRE. One-quarter of LT recipients were found to be colonized with CRE prior LT (63/250, 25.7%). KPC genotype was the most common mechanism of resistance (183/250, 73.2%).

CRE infection episodes included 91 BSI (36.4%), of which 38.5% were classified as primary; 59 lower respiratory tract infections (23.6%), 52 intra-abdominal infections (20.8%), and 65 surgical site infections (26%). The median time from LT to CRE infection was 19 days (IQR 9–42). Vasopressors were administered in 49/250 cases (39.6%), 114/250 patients (45.6%) required mechanical ventilation. In vitro active empirical therapy was started in 147 patients (58.8%). Among targeted treatments, polymyxin-based regimen was administered in 114 cases (60%), followed by aminoglycoside-based (39, 20.5%), and tigecycline-based regimens (33, 17.4%; of these 30/33 had intra-abdominal infection and 10/33 presented with septic shock). Only four patients (2.1%) received ceftazidime/avibactam. The all-cause 30-day mortality was 35.6%. Among scores calculated at CRE infection onset, median INCREMENT-SOT-CPE, ICS, PITT, qPITT, and SOFA score were 10 (IQR 7–13), 8 (IQR 6–14), 3 (IQR 1–6), 2 (IQR 0–3), and 8 (IQR 5–13), respectively. The comparison between survivors and non-survivors with CRE infection is shown in Table 1.

The likelihood-ratio test comparing two-level mixed effects logistic regression model with ordinary logistic regression for each score showed that the former is the most accurate model (Table S2). Sensitivity, specificity, PPV, NPV, and accuracy for each selected score are shown in Table 2. In particular, a SOFA score ≥ 11 showed a sensitivity, specificity, PPV, NPV, and accuracy of 69.7% (95% CI: 59.0%–79.0%), 76.4% (95% CI: 69.1%–82.7%), 62.0% (95% CI: 51.7%–71.5%), 82.0% (95% CI: 74.9%–87.8%), and 74.0% (95% CI: 68.6%–79.4%), respectively. An INCREMENT-SOT-CPE ≥ 11 reported a sensitivity, specificity, PPV, NPV, and accuracy of 73.0% (95% CI: 62.6%–81.9%), 62.1% (95% CI: 54.1%–69.6%), 51.6% (95% CI: 42.5%–60.6%), 80.6% (95% CI: 72.6%–87.2%), and 66.0% (95% CI: 60.1%–71.9%), respectively. The ROC curves for each selected score are shown in Figure 1. Of note, the diagnostic characteristics for each selected score along with ROC curves analysis among those patients with and without BSI were similar to the main analysis on all infection sites (see Tables S3 and S4, and Figures S1 and S2). In addition, subgroup analyses among patients admitted or not to the ICU at the time of developing the infection are reported in Tables S5 and Table S6, and Figures S3 and S4.

At multivariable Cox regression analysis, we found a significant frailty effect, meaning that the correlation within centers cannot be




FIGURE 1 Receiver operating characteristic (ROC) curve for each selected score.

ignored ($p = .043$). The independent risk factors for all-cause 30-day mortality were acute renal failure, prolonged mechanical ventilation, INCREMENT-SOT-CPE score ≥ 11 , and SOFA score ≥ 11 , while tigecycline-based regimen was associated to a lower risk (Table 3). Of note, the assumption of proportional hazard was violated for the SOFA score ($p = .039$) (Figures S5 and S6). The visual analysis suggested a greater effect for SOFA ≥ 11 in the first week (i.e., 0–7 day time interval) compared to 8–30 day time interval. The final Cox model with shared frailty included a time-dependent covariate for SOFA showing a higher risk for SOFA ≥ 11 in 0–7 day time interval (Table 3).

4 | DISCUSSION

We performed an external validation of the INCREMENT-SOT-CPE score compared to other selected prognostic scores in a large, multicenter, international cohort of LT recipients colonized with CRE and who developed CRE infection after transplantation. Although an INCREMENT-SOT-CPE score ≥ 11 was independently associated with a higher mortality risk, SOFA score was more accurate in the setting of liver transplantation, with a greater effect for SOFA ≥ 11 in the first week.

The INCREMENT-SOT-CPE score was first derived from a mixed cohort of SOT recipients, in which LT recipients accounted for 56%. Some variables included in the INCREMENT-SOT-CPE score, such as lymphopenia and CMV infection after transplantation, are related to the net state of immunosuppression of the recipient.^{24,25} Generally, these complications occurred more frequently in non-LT recipients due to the more intensive immunosuppression regimens used in those patients.²⁶ This issue may partially explain the difference in accuracy of INCREMENT-SOT-CPE to predict mortality in patients with CRE infection between our cohort of LT recipients and that of the derivation study. Furthermore, INCREMENT-SOT-CPE score was developed considering only BSI, excluding other types of nonbacteremic infections, while we analyzed all types of CRE infections diagnosed in colonized patients including BSI (36.4%), lower respiratory tract (24%), and

TABLE 1 Univariable analysis between survivors and non-survivors LT recipients with CRE infection.

	Survivors N = 161	Non-survivors N = 89	Total N = 250	p-Value
Demographic data				
Age (years), median (IQR)	55 (47–62)	56 (44–63)	55 (46–62)	.953
Sex, male	97 (60.3)	60 (67.4)	157 (62.8)	.262
Comorbidities				
Myocardial infarction	5 (3.1)	1 (1.1)	6 (2.4)	.426
Congestive heart failure	8 (5.0)	2 (2.3)	10 (4.0)	.502
Peripheral vascular disease	4 (2.5)	2 (2.3)	6 (2.4)	1.000
Cerebrovascular disease	4 (2.5)	2 (2.3)	6 (2.4)	1.000
COPD	6 (3.7)	10 (11.2)	16 (6.4)	.020
Diabetes without organ damage	27 (16.8)	15 (16.9)	42 (16.8)	.986
Moderate/severe renal disease	19 (11.8)	17 (19.1)	36 (14.4)	.115
Diabetes with organ damage	15 (9.3)	6 (6.7)	21 (8.4)	.482
Any tumor within 5 years	61 (37.9)	16 (18.0)	77 (30.8)	.001
Charlson index, mean (SD)	5.6 (2.0)	5.3 (1.9)	5.5 (2.0)	.147
Underlying liver disease				
Viral hepatitis	80 (49.7)	34 (38.2)	114 (45.6)	.081
Alcohol	34 (21.1)	15 (16.9)	49 (19.6)	.416
Metabolic disease	16 (9.9)	5 (5.6)	21 (8.4)	.238
Autoimmune disease	9 (5.6)	2 (2.3)	11 (4.4)	.337
Fulminant hepatitis	6 (3.7)	10 (11.2)	16 (6.4)	.020
Hepatocellular carcinoma	55 (34.2)	16 (18)	71 (28.4)	.007
Prior transplant	7 (4.3)	7 (7.9)	14 (5.6)	.262
MELD at inclusion in waiting list, median (IQR)	19 (14–25)	19 (15–31)	19 (14–27)	.257
MELD at LT, median (IQR)	24 (16–30)	29 (18–37)	25 (16–32)	.004
CRE carriage management				
Targeted peri-operative prophylaxis	10 (6.2)	3 (3.4)	13 (5.2)	.390
Selective decolonization	4 (2.5)	0 (0)	4 (1.6)	.300
Postoperative complications				
Acute renal failure	96 (59.6)	80 (89.9)	176 (70.4)	<.001
Renal replacement therapy	63 (39.1)	65 (73.0)	128 (51.2)	<.001
Mechanical ventilation >48 h	70 (43.5)	62 (69.7)	132 (52.8)	<.001
PGNF	23 (14.3)	31 (34.8)	54 (21.6)	<.001
Re-intervention	81 (50.3)	42 (47.2)	123 (49.2)	.637
Re-transplantation	25 (15.5)	12 (13.5)	37 (14.8)	.663
Rejection	29 (18.0)	21 (23.6)	50 (20.0)	.291
CMV infection	50 (31.1)	20 (22.5)	70 (28.0)	.148
Infections other than CRE	89 (55.3)	57 (64.0)	146 (58.4)	.178
CRE carriage				
CRE acquisition pre LT	38 (24.4)	25 (28.1)	63 (25.7)	.520
CRE acquisition post LT	118 (75.6)	64 (71.9)	182 (74.3)	.520
Genotype of the strain				
KPC	121 (75.2)	62 (69.7)	183 (73.2)	.348
VIM	1 (0.6)	2 (2.3)	3 (1.2)	.289
OXA-48	3 (1.9)	3 (3.4)	6 (2.4)	.669

(Continues)

TABLE 1 (Continued)

	Survivors N = 161	Non-survivors N = 89	Total N = 250	p-Value
Infection site				
BSI	58 (36.0)	33 (37.1)	91 (36.4)	.868
Primary	21/58 (36.2)	14/33 (42.4)	35/91 (38.5)	
Secondary	24/58 (41.4)	13/33 (39.4)	37/91 (40.7)	
CVC device related	13/58 (22.4)	6/33 (18.2)	19/91 (20.9)	
Lower respiratory tract	32 (19.9)	27 (30.3)	59 (23.6)	.062
Intra-abdominal	34 (21.1)	18 (20.2)	52 (20.8)	.868
Urinary tract	20 (12.4)	3 (3.4)	23 (9.2)	.021
Surgical site	39 (24.2)	26 (29.2)	65 (26.0)	.389
Infection severity				
SOFA score, median (IQR)	5 (4–9)	13 (6–16)	8 (5–13)	<.001
qPITT score, median (IQR)	1 (0–2)	3 (2–3)	2 (0–3)	<.001
PITT score, median (IQR)	2 (0–5)	6 (3–9)	3 (1–6)	<.001
INCREMENT-CPE, median (IQR)	6 (5–11)	12 (7–15)	8 (6–14)	<.001
INCREMENT-SOT-CPE, median (IQR)	10 (4–12)	12 (8–14)	10 (7–13)	.002
Septic shock	40 (24.8)	55 (61.8)	95 (38.0)	<.001
Antibiotic treatment				
In vitro active empirical treatment	94 (58.4)	53 (59.6)	147 (58.8)	.858
Targeted treatment				
Combination therapy vs. monotherapy	134 (86.5)	60 (87.0)	194 (86.6)	.918
Targeted regimens				
Polymyxin based	72 (54.5)	42 (72.4)	114 (60.0)	.024
Aminoglycoside based	27 (20.5)	12 (20.7)	39 (20.5)	
Tigecycline based	29 (22.0)	4 (6.9)	33 (17.4)	
CZA based	4 (3.0)	0 (0.0)	4 (2.1)	

Note: All values given are n (%) unless otherwise stated.

Abbreviations: BSI, bloodstream infection; CMV, *Cytomegalovirus*; COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacteriales; CVC, central venous catheter; CZA, ceftazidime/avibactam; IQR, interquartile range; LT, liver transplant; MELD, model for end-stage liver disease; PGNF, primary graft non-function; SD, standard deviation.

TABLE 2 Diagnostic characteristics for INCREMENT-SOT-CPE score along with other selected scores

Score	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Accuracy (95% CI)
SOFA \geq 11	69.7% (59.0%–79.0%)	76.4% (69.1%–82.7%)	62.0% (51.7%–71.5%)	82.0% (74.9%–87.8%)	74.0% (68.6%–79.4%)
PITT \geq 4	70.8% (60.2%–79.9%)	71.4% (63.8%–78.3%)	57.8% (48.0%–67.2%)	81.6% (74.2%–87.6%)	71.2% (65.6%–76.8%)
qPITT \geq 3	64.0% (53.2%–73.9%)	77.6% (70.4%–83.8%)	61.3% (50.6%–71.2%)	79.6% (72.5%–85.6%)	72.8% (67.3%–78.3%)
INCREMENT-SOT-CPE \geq 11	73.0% (62.6%–81.9%)	62.1% (54.1%–69.6%)	51.6% (42.5%–60.6%)	80.6% (72.6%–87.2%)	66.0% (60.1%–71.9%)
ICS \geq 12	65.2% (54.3%–75.0%)	76.4% (69.1%–82.7%)	60.4% (49.9%–70.3%)	79.9% (72.7%–85.9%)	72.4% (66.9%–77.9%)

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.

TABLE 3 Multivariable Cox regression analysis for all-cause 30-day mortality from infection

Variable	HR (95% CI) ^a	p-Value
Acute renal failure	2.79 (1.23–6.32)	.014
Mechanical ventilation \geq 48 h	1.90 (1.09–3.30)	.024
Tigecycline-based regimen	0.25 (0.09–0.70)	.009
INCREMENT-SOT-CPE \geq 11	1.83 (1.09–3.07)	.023
SOFA \geq 11		
0–7 days	4.13 (1.47–11.59)	.007
8–30 days	2.49 (1.37–4.50)	.003

^aA Cox model with shared frailty that included a time-dependent covariate for SOFA \geq 11 was fitted (see Statistical Methods).

intra-abdominal (21%) infections. However, despite BSI accounted for only one-third of cases in our cohort, the 30-day mortality rate (35.6%) was similar to that observed in the derivation cohort (36.6%). In addition, in the study by Perez-Nadales et al., an INCREMENT-SOT-CPE score \geq 12 identifies the “very high-risk” group. Similarly, in our cohort, a score \geq 11 was associated with an almost two-fold risk of short-term death.

SOFA score showed the best accuracy in predicting 30-day mortality. As a significant rate of CRE infections accounted in ICU, these results are expected considering the high accuracy of such score in this specific setting. A recent case-control study performed in ICU highlighted the importance of SOFA score as an independent risk factor for short-term mortality in critically ill patients with CPE bacteremia.²⁷ Although our cohort was composed of SOT recipients, at multivariable analysis a SOFA score \geq 11 was confirmed as an independent risk factor for 30-day mortality. Such issue was already underlined in a small cohort of kidney transplant recipients infected with CPE, in which at multivariable analysis an elevated SOFA score was the only risk factor associated with mortality.²⁸

Other variables retained in the multivariable analysis, such as acute renal failure and prolonged mechanical ventilation, are well-known postoperative complications strictly associated with CRE colonization, infection, and burdened by high mortality rates.^{29,30}

Considering targeted therapies, a trend toward increased mortality in patients treated with a polymyxin-based regimen was observed, on the other hand no differences were reported among aminoglycoside-based regimen. Of interest, a tigecycline-based regimen was found to have a protective impact on 30-day mortality. Such finding could be explained by the almost exclusive use in abdominal infections (91%) where the pharmacokinetic/pharmacodynamic behavior of tigecycline is favorable.^{31,32} However, other confounding bias influencing this feature cannot be excluded. The potential role of a combination therapy based on tigecycline was already mentioned in a retrospective cohort of abdominal SOT recipients infected with carbapenem-resistant gram-negative pathogens, even if an increasing rate of resistance over the study period was recorded.³³

Despite the limitation of retrospective studies, we applied strict definitions and performed several revisions of data with local inves-

tigators to solve concerns about missing or incongruous data, as well as multivariable analyses to ensure high quality of data and minimization of potential confounding bias. The limited use of new anti-CRE drugs in our cohort could be seen as another limitation. On this regard, it is worth noting that accessibility to such new drugs is still limited in several world areas. However, we recognize that the impact of the new drugs in mortality rates and in the management of CRE colonization/infection in SOT recipients is a key issue deserving further investigations. Finally, our cohort was burdened by a high prevalence of KPC-producing Enterobacterales, with a very low number of other resistance mechanisms detected. In addition, all patients enrolled in our cohort were CRE carriers, of these three-quarters acquired colonization after LT. Such issue could have created a selection bias.

In conclusion, in colonized LT recipients with CRE infection, SOFA score showed the highest accuracy in predicting 30-day mortality risk, suggesting a greater effect for SOFA \geq 11 in the first week within infection onset. However, an INCREMENT-SOT-CPE score \geq 11 was confirmed as a strong predictor of mortality. Compared to other “old” anti-CRE treatments, a tigecycline-based regimen was found to be protective on 30-day mortality.

AUTHOR CONTRIBUTIONS

Matteo Rinaldi: interpretation of data and paper drafting. Cecilia Bonazzetti, Giuseppe Ferraro, Débora Raquel Benedita Terrabuio, Alberto Ferrarese, Elizabeth Balbi, Lilian Abbo, Mireia Cantero, Laura Alagna, Wanessa Trindade Clemente, Maricela Valerio, and Liran Statlender: data acquisition. Mena Gallo: data analysis. Maristela Freire: work design. Francesco Tandoi, Renato Romagnoli, Francesco Giuseppe De Rosa, Patrizia Burra, Marcia Halpern, Jacques Simkins, Ignacio Morrás, Alessandra Bandera, Ainhoa Fernández, Patricia Muñoz, Dafna Yahav, Luis Fernando Aranha Camargo, Evelyne Santana Girão, and Paolo Grossi: draft revision. Alessandra Mularoni: data acquisition and draft revision. Pierluigi Viale: final approval and draft revision. Stefania Curti: data analysis and final revision. Maddalena Giannella: conceptualization, draft revision, and final approval.

AFFILIATIONS

¹Infectious Diseases Unit, IRCCS Sant’Orsola Hospital, Bologna, Italy

²Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

³Working Committee for Hospital Epidemiology and Infection Control, Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil

⁴Infectious Diseases Department, Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil

⁵Department of Surgical Sciences, Liver Transplant Center, General Surgery Unit, AOU Città della Salute e della Scienza, Molinette Hospital, University of Turin, Turin, Italy

⁶University Infectious Diseases, University of Turin, Turin, Piemonte, Italy

⁷Infectious Diseases, ISMETT IRCCS, Palermo, Italy

⁸Department of Surgery Oncology and Gastroenterology, Multivisceral Transplant Unit (Gastroenterology), Surgical and Gastroenterological Sciences, Padua University Hospital, Padua, Italy

⁹Liver Transplant Unit, Quinta D’Or Hospital, Rio de Janeiro, Brazil



¹⁰Transplant Infectious Diseases and Immunocompromised Host Service, Division of Infectious Diseases, University of Miami/Miami Transplant Institute, Miami, Florida, USA

¹¹Department of Medicine, Division of Infectious Diseases, University of Miami, Miami, Florida, USA

¹²Servicio de Medicina Interna, HU Puerta de Hierro-Majadahonda, Madrid, Spain

¹³Servicio de Medicina Preventiva, HU Puerta de Hierro-Majadahonda, Madrid, Spain

¹⁴Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

¹⁵Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

¹⁶Transplant Unit and Infection Control Commission, Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

¹⁷Department of Clinical Microbiology and Infectious Diseases, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain

¹⁸Department of Gastroenterology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain

¹⁹Intensive Care Unit, Rabin Medical Center, Petah Tikva, Israel

²⁰Infectious Disease Unit, Beilinson Hospital, Petah Tikva, Israel

²¹Infectious Diseases Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil

²²Infectious Diseases Unit and Liver Transplant Unit of Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brazil

²³Infectious Disease Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy

ACKNOWLEDGMENTS

Open Access Funding provided by Università degli Studi di Bologna within the CRUI-CARE Agreement.

CONFLICT OF INTEREST STATEMENT

The authors have no conflict of interest related to the present study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Matteo Rinaldi  <https://orcid.org/0000-0002-3568-5973>

Maristela Freire  <https://orcid.org/0000-0002-9691-192X>

Alessandra Mularoni  <https://orcid.org/0000-0001-8612-5581>

Jacques Simkins  <https://orcid.org/0000-0001-9626-0760>

Lilian Abbo  <https://orcid.org/0000-0003-1974-4547>

Maricela Valerio  <https://orcid.org/0000-0001-6394-2861>

Patricia Muñoz  <https://orcid.org/0000-0002-0697-3992>

Dafna Yahav  <https://orcid.org/0000-0003-3181-9791>

Maddalena Giannella  <https://orcid.org/0000-0001-8273-7601>

REFERENCES

- Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis.* 2017;215(1):S28-S36.
- Giannella M, Bartoletti M, Campoli C, et al. The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. *Clin Microbiol Infect.* 2019;25(12):1525-1531.
- Qiao B, Wu J, Wan Q, Zhang S, Ye Q. Factors influencing mortality in abdominal solid organ transplant recipients with multidrug-resistant gram-negative bacteremia. *BMC Infect Dis.* 2017;17(1):171.
- Giannella M, Freire M, Rinaldi M, et al. Development of a risk prediction model for carbapenem-resistant Enterobacteriaceae infection after liver transplantation: a multinational cohort study. *Clin Infect Dis.* 2021;73(4):e955-e966.
- Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, et al. External validation of INCREMENT-CPE score in a retrospective cohort of carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections in critically ill patients. *Clin Microbiol Infect.* 2021;27(6):915.e1-915.e3.
- Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, et al. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant *Klebsiella pneumoniae* bacteraemia cohort: the prognostic significance of colistin resistance. *Int J Antimicrob Agents.* 2019;54(4):442-448.
- Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in patients with carbapenem-resistant Enterobacteriaceae infections treated with ceftazidime-avibactam. *Infect Dis Ther.* 2020;9(2):291-304.
- Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, et al. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacteriales: the impact of cytomegalovirus disease and lymphopenia. *Am J Transplant.* 2020;20(6):1629-1641.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-381.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control.* 2008;36(5):309-332.
- Al-Hasan MN, Juhn YJ, Bang DW, Yang HJ, Baddour LM. External validation of bloodstream infection mortality risk score in a population-based cohort. *Clin Microbiol Infect.* 2014;20(9):886-891.
- Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of *Klebsiella pneumoniae* bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. *Ann Intern Med.* 2004;140(1):26-32.
- Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med.* 2009;37(5):1649-1654.
- Battle SE, Augustine MR, Watson CM, et al. Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection. *Infection.* 2019;47(4):571-578.
- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract.* 2012;120(4):c179-c184.
- Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. *Clin Transplant.* 2019;33(10):e13666.
- Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. *Biom J.* 2005;47(4):458-472.

19. Bouwmeester W, Twisk JW, Kappen TH, van Klei WA, Moons KG, Vergouwe Y. Prediction models for clustered data: comparison of a random intercept and standard regression model. *BMC Med Res Methodol*. 2013;13(1):19.
20. Wynants L, Vergouwe Y, Van Huffel S, Timmerman D, Van Calster B. Does ignoring clustering in multicenter data influence the performance of prediction models? A simulation study. *Stat Methods Med Res*. 2018;27(6):1723-1736. <https://doi.org/10.1177/0962280216668555>
21. Gelman A, Hill J. *Data Analysis Using Regression and Multilevel/Hierarchical Models*. Cambridge University Press; 2006. Accessed June 25, 2022. <https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983>
22. Balan TA, Putter H. A tutorial on frailty models. *Stat Methods Med Res*. 2020;29(11):3424-3454.
23. Kleinbaum DG, Klein M, eds. *Survival analysis*. Accessed June 25, 2022. <https://link.springer.com/book/10.1007/978-1-4419-6646-9>
24. Azevedo LS, Pierrotti LC, Abdala E, et al. *Cytomegalovirus* infection in transplant recipients. *Clinics (Sao Paulo)*. 2015;70(7):515-523.
25. Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the "net state of immunosuppression." *Clin Infect Dis*. 2020;73(7):e1302-e1317.
26. Han SH, Yoo SG, Do Han K, La Y, Kwon DE, Lee KH. The incidence and effect of *Cytomegalovirus* disease on mortality in transplant recipients and general population: real-world nationwide cohort data. *Int J Med Sci*. 2021;18(14):3333-3341.
27. Papadimitriou-Olivgeris M, Fligou F, Bartzavali C, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infection in critically ill patients: risk factors and predictors of mortality. *Eur J Clin Microbiol Infect Dis*. 2017;36(7):1125-1131.
28. Freire MP, Abdala E, Moura ML, et al. Risk factors and outcome of infections with *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* in kidney transplant recipients. *Infection*. 2015;43(3):315-323.
29. Giannella M, Trecarichi EM, Rosa FGD, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational multicenter study. *Clin Microbiol Infect*. 2014;20(12):1357-1362.
30. Freire MP, Oshiro ICVS, Pierrotti LC, et al. Carbapenem-resistant Enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes. *Transplantation*. 2017;101(4):811-820.
31. Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2016;95(11):e3126.
32. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. *Expert Opin Drug Metab Toxicol*. 2011;7(11):1459-1470.
33. Wu D, Chen C, Liu T, Jia Y, Wan Q, Peng J. Epidemiology, susceptibility, and risk factors associated with mortality in carbapenem-resistant gram-negative bacterial infections among abdominal solid organ transplant recipients: a retrospective cohort study. *Infect Dis Ther*. 2021;10(1):559-573.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Rinaldi M, Bonazzetti C, Gallo M, et al. Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacteriales infection. *Transpl Infect Dis*. 2023;25:e14036. <https://doi.org/10.1111/tid.14036>

APPENDIX: CRECOOLT study group

Italy:

Bologna, IRCCS Policlinico di Sant'Orsola, Michele Bartoletti, Renato Pascale, Caterina Campoli, Simona Coladonato, Francesco Cristini, Fabio Tumietto, Antonio Siniscalchi, Cristiana Laici, Simone Ambretti. Torino, AOU Città della Salute e della Scienza di Torino, Renato Romagnoli, Francesco Giuseppe De Rosa. Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Antonio Muscatello, Davide Mangioni, Andrea Gori, Barbara Antonelli, Daniele Dondossola, Giorgio Rossi, Federica Invernizzi. Udine, Azienda Sanitaria Universitaria Integrata di Udine, Maddalena Peghin. Padova, Azienda Ospedale Università di Padova, Umberto Cillo. Modena, Azienda Ospedaliero - Universitaria di Modena, Cristina Mussini, Fabrizio Di Benedetto. Palermo, ISMETT IRCCS.

Brazil:

São Paulo, Hospital das Clínicas, Universidade de São Paulo, Débora Raquel Benedita Terrabuio. São Paulo, Hospital Israelita Albert Einstein, Carolina D Bittante, Alexandra do Rosário Toniolo. Rio de Janeiro, Quinta D'Or Hospital, Elizabeth Balbi. Fortaleza, Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, José Huygens Parente Garcia.

Spain:

Majadahonda, Puerta de Hierro-Majadahonda University Hospital, Angel Asensio, Ignacio Morrás, Antonio Ramos. Madrid: Hospital General Universitario Gregorio Marañón, Magdalena Salcedo.

Israel:

Petah-Tikva, Beilinson Hospital.

US:

Miami, University of Miami/Miami Transplant Institute.